Paolo Rossi
Research Subjects
Paolo Rossi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
G Nappi
University Centre for Adaptive Disorders and Headache, IRCCS ‘C. Mondino Institute of Neurology’ Foundation, Pavia, Italy
4 shared publicationsGiuseppe Nappi
University Centre for Adaptive Disorders and Head Pain (UCADH), Italy
4 shared publications- Giorgio Di Lorenzo
University of Rome Tor Vergata
3 shared publications Cristina Tassorelli
University Centre for Adaptive Disorders and Head Pain (UCADH), Italy
2 shared publicationsG. Nappi
Headache Unit & UCADH, IRCCS ‘C. Mondino National Institute of Neurology’ Foundation, Pavia
2 shared publicationsGrazia Sances
Headache Science Centre, IRCCS C. Mondino National Institute of Neurology Foundation and University of Pavia, Italy
2 shared publications
Latest Publications
- Open Access
- 8 February 2013
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 14 (1) , 10
Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial
The aim of this study was to compare the effectiveness of an educational strategy (advice to withdraw the overused medication/s) with that of two structured pharmacological detoxification programmes in patients with complicated medication overuse headache (MOH) plus migraine. One hundred and thirty-seven complicated MOH patients participated in the study. MOH was defined as complicated in patients presenting at least one of the following: a) a diagnosis of co-existent and complicating medical illnesses; b) a current diagnosis of mood disorder, anxiety disorder, eating disorder, or substance addiction disorder; c) relapse after previous detoxification treatment; d) social and environmental problems; e) daily use of multiple doses of symptomatic medications. Group A (46 patients) received only intensive advice to withdraw the overused medication/s. Group B (46 patients) underwent a standard detoxification programme as outpatients (advice + steroids + preventive treatment). Group C (45 patients) underwent a standard inpatient withdrawal programme (advice + steroids + fluid replacement and antiemetics preventive treatment). Withdrawal therapy was considered successful if, after two months, the patient had reverted to an intake of NSAIDs lower than 15 days/month or to an intake of other symptomatic medication/s lower than 10 days/month. Twenty-two patients failed to attend follow-up visits (11 in Group A, 9 in Group B, 2 in Group C, p < 0.03). Overall, we detoxified 70% of the whole cohort, 60.1% of the patients in Group A and in Group B, and 88.8% of those in Group C (p < 0.01). Inpatient withdrawal is significantly more effective than advice alone or an outpatient strategy in complicated MOH patients.
- 8 February 2013
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 14 (1) , 10
Open AccessAdvice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial
The aim of this study was to compare the effectiveness of an educational strategy (advice to withdraw the overused medication/s) with that of two structured pharmacological detoxification programmes in patients with complicated medication overuse headache (MOH) plus migraine. One hundred and thirty-seven complicated MOH patients participated in the study. MOH was defined as complicated in patients presenting at least one of the following: a) a diagnosis of co-existent and complicating medical illnesses; b) a current diagnosis of mood disorder, anxiety disorder, eating disorder, or substance addiction disorder; c) relapse after previous detoxification treatment; d) social and environmental problems; e) daily use of multiple doses of symptomatic medications. Group A (46 patients) received only intensive advice to withdraw the overused medication/s. Group B (46 patients) underwent a standard detoxification programme as outpatients (advice + steroids + preventive treatment). Group C (45 patients) underwent a standard inpatient withdrawal programme (advice + steroids + fluid replacement and antiemetics preventive treatment). Withdrawal therapy was considered successful if, after two months, the patient had reverted to an intake of NSAIDs lower than 15 days/month or to an intake of other symptomatic medication/s lower than 10 days/month. Twenty-two patients failed to attend follow-up visits (11 in Group A, 9 in Group B, 2 in Group C, p < 0.03). Overall, we detoxified 70% of the whole cohort, 60.1% of the patients in Group A and in Group B, and 88.8% of those in Group C (p < 0.01). Inpatient withdrawal is significantly more effective than advice alone or an outpatient strategy in complicated MOH patients.
- 11 September 2012
- Published by SAGE Publications in Cephalalgia
- Vol. 32 (14) , 1031-1040
Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey
Background: The rate of illicit drug use in cluster headache (CH) patients is unknown. Methods: Two hundred and ten CH patients (162 males and 48 females) attending two headache clinics provided information about their lifetime use (once or more in their lifetime, LTU), recent use (once or more in the past year, RU), and current use (once or more in the past 30 days, CU) of illicit drugs. General population data (IPSAD®Italia2007–2008) served as the control group. Results: LTU of each illicit drug but hallucinogens, RU of cannabis, cocaine, amphetamines and ecstasy, and CU of cannabis and cocaine were significantly higher in the male CH patients than in the general population, whereas no difference was found between the CH women and the controls. In the CH group, 28.5% of patients reported having used illicit drugs for the first time after CH onset and 71.5% before CH onset. Compared with the controls, the male CH group showed a greater prevalence both of lifetime sustained intensive use of any illicit drug and of current intensive use of cannabis. Conclusion: The results of this study indicate that male CH patients are prone to overindulge in illicit drug use. This finding possibly reflects a common biological susceptibility that predisposes these subjects to CH and to addictive behaviour.
- 11 September 2012
- Published by SAGE Publications in Cephalalgia
- Vol. 32 (14) , 1031-1040
Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey
Background: The rate of illicit drug use in cluster headache (CH) patients is unknown. Methods: Two hundred and ten CH patients (162 males and 48 females) attending two headache clinics provided information about their lifetime use (once or more in their lifetime, LTU), recent use (once or more in the past year, RU), and current use (once or more in the past 30 days, CU) of illicit drugs. General population data (IPSAD®Italia2007–2008) served as the control group. Results: LTU of each illicit drug but hallucinogens, RU of cannabis, cocaine, amphetamines and ecstasy, and CU of cannabis and cocaine were significantly higher in the male CH patients than in the general population, whereas no difference was found between the CH women and the controls. In the CH group, 28.5% of patients reported having used illicit drugs for the first time after CH onset and 71.5% before CH onset. Compared with the controls, the male CH group showed a greater prevalence both of lifetime sustained intensive use of any illicit drug and of current intensive use of cannabis. Conclusion: The results of this study indicate that male CH patients are prone to overindulge in illicit drug use. This finding possibly reflects a common biological susceptibility that predisposes these subjects to CH and to addictive behaviour.
- 17 February 2011
- Published by Wiley in European Journal of Neurology
- Vol. 18 (3) , 396-401
Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache
The aim of this study was to compare the effectiveness of intensive advice (to withdraw the overused medication/s) as a withdrawal strategy in patients with simple and complicated medication overuse headache (MOH). One hundred consecutive MOH patients were included in the study. Exclusion criteria were co-existent severe medical or psychiatric illnesses, treatment with migraine prophylactic drugs within the past 3 months, and overuse of opioids and/or barbiturate-containing agents. MOH was defined as complicated in patients fulfilling at least one of the following criteria: (i) a diagnosis of co-existent, significant, and complicating medical illnesses; (ii) a current diagnosis of mood disorder, anxiety disorder, eating disorder, or substance addiction disorder; (iii) a relapse after previous detoxification treatment; (iv) psycho-social and environmental problems; and (v) daily use of multiple doses of symptomatic medication/s. Withdrawal therapy was considered successful if, after 2 months, the patient had had reverted to an intake of NSAIDs lower than 15 days/month or to an intake of other symptomatic medication/s lower than 10 days/month. Fifty-one patients had simple MOH and 49 patients had complicated MOH. Eleven patients failed to attend follow-up visits (simple MOH=3, complicated MOH=8, P>0.05). Of all the patients included in the study, we were able to detoxify 79% (92.1% of the patients with simple MOH and 65.3% of those with complicated MOH, P<0.01). Simple advice is highly effective in simple MOH and effective in most complicated MOH patients and should be regarded as the first step in a step-care approach to MOH management.
- 17 February 2011
- Published by Wiley in European Journal of Neurology
- Vol. 18 (3) , 396-401
Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache
The aim of this study was to compare the effectiveness of intensive advice (to withdraw the overused medication/s) as a withdrawal strategy in patients with simple and complicated medication overuse headache (MOH). One hundred consecutive MOH patients were included in the study. Exclusion criteria were co-existent severe medical or psychiatric illnesses, treatment with migraine prophylactic drugs within the past 3 months, and overuse of opioids and/or barbiturate-containing agents. MOH was defined as complicated in patients fulfilling at least one of the following criteria: (i) a diagnosis of co-existent, significant, and complicating medical illnesses; (ii) a current diagnosis of mood disorder, anxiety disorder, eating disorder, or substance addiction disorder; (iii) a relapse after previous detoxification treatment; (iv) psycho-social and environmental problems; and (v) daily use of multiple doses of symptomatic medication/s. Withdrawal therapy was considered successful if, after 2 months, the patient had had reverted to an intake of NSAIDs lower than 15 days/month or to an intake of other symptomatic medication/s lower than 10 days/month. Fifty-one patients had simple MOH and 49 patients had complicated MOH. Eleven patients failed to attend follow-up visits (simple MOH=3, complicated MOH=8, P>0.05). Of all the patients included in the study, we were able to detoxify 79% (92.1% of the patients with simple MOH and 65.3% of those with complicated MOH, P<0.01). Simple advice is highly effective in simple MOH and effective in most complicated MOH patients and should be regarded as the first step in a step-care approach to MOH management.
- Open Access
- 4 December 2009
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 11 (1) , 85
Erratum to: A narrative review on the management of medication overuse headache: the steep road from experience to evidence
- 4 December 2009
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 11 (1) , 85
Open AccessErratum to: A narrative review on the management of medication overuse headache: the steep road from experience to evidence
- Open Access
- 3 October 2009
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 10 (6) , 407-417
A narrative review on the management of medication overuse headache: the steep road from experience to evidence
The Journal of Headache and Pain is a peer-reviewed open access journal published under the brand SpringerOpen. It is specifically dedicated to researchers involved in all aspects of headache and related pain, including theory, methodology, clinical practice and care. The journal's scope is broad, reflecting the wide application of scientific advances to every branch of headache and related pain management. Within a multidisciplinary perspective, the Journal covers headache and related pain syndromes in the following fields: genetics, neurology, internal medicine, clinical pharmacology, child neuropediatrics, anesthesiology, rheumatology, otology, dentistry, neurotraumatology, neurosurgery, psychiatry, pain management, and addiction. The Journal of Headache and Pain publishes original papers, reviews, rapid communications, brief reports, and letters pertinent to the various aspects of headache and related pain. Researchers in all basic and clinical fields of headache and related pain, from molecular biology to genetics, from epidemiology to classification, from quality of life assessment to clinical trials, are becoming increasingly aware of the importance of this medical specialty. Official Journal of the European Headache Federation Official Journal of Lifting The Burden - The Global Campaign against Headache For authors and readers: All articles are published under the Creative Commons Attribution licence. You can read, redistribute and reuse the articles for free, as long as you cite the authors of the original work properly. The journal went open access in 2011, which means that all articles published since then are freely available online.
- 3 October 2009
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 10 (6) , 407-417
Open AccessA narrative review on the management of medication overuse headache: the steep road from experience to evidence
The Journal of Headache and Pain is a peer-reviewed open access journal published under the brand SpringerOpen. It is specifically dedicated to researchers involved in all aspects of headache and related pain, including theory, methodology, clinical practice and care. The journal's scope is broad, reflecting the wide application of scientific advances to every branch of headache and related pain management. Within a multidisciplinary perspective, the Journal covers headache and related pain syndromes in the following fields: genetics, neurology, internal medicine, clinical pharmacology, child neuropediatrics, anesthesiology, rheumatology, otology, dentistry, neurotraumatology, neurosurgery, psychiatry, pain management, and addiction. The Journal of Headache and Pain publishes original papers, reviews, rapid communications, brief reports, and letters pertinent to the various aspects of headache and related pain. Researchers in all basic and clinical fields of headache and related pain, from molecular biology to genetics, from epidemiology to classification, from quality of life assessment to clinical trials, are becoming increasingly aware of the importance of this medical specialty. Official Journal of the European Headache Federation Official Journal of Lifting The Burden - The Global Campaign against Headache For authors and readers: All articles are published under the Creative Commons Attribution licence. You can read, redistribute and reuse the articles for free, as long as you cite the authors of the original work properly. The journal went open access in 2011, which means that all articles published since then are freely available online.
- 15 July 2009
- Published by Wiley in European Journal of Neurology
- Vol. 16 (8) , 937-942
Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non‐acute migraine patients: a questionnaire survey of neurologists and primary care physicians
Background and purpose: The main aims of this study were to evaluate: the diffusion, use and perception of the usefulness of the 2004 EFNS guidelines on neurophysiological testing in non‐acute headache patients; the frequency with which the different neurophysiological tests were recommended in non‐acute migraine patients by physicians aware or unaware of the guidelines; and the appropriateness of the reasons given for recommending neurophysiological tests. Methods: One hundred and fifty physicians selected amongst the members of the Italian societies of general practitioner (GPs), neurologists and headache specialists were contacted via e‐mail and invited to fill in a questionnaire specially created for the study. Results: Ninety‐two percent of the headache specialists, 8.6% of the neurologists and 0% of the GPs were already aware of the EFNS guidelines. A significantly higher proportion of headache specialists had not recommended any neurophysiological tests to the migraine patients they had seen in the previous 3 months, whereas these tests had frequently been prescribed by the GPs and neurologists. Overall, 80%, 42% and 42.6% of the reasons given by headache specialists, neurologists and GPs, respectively, for recommending neurophysiological testing in their migraine patients were appropriate (P < 0.01). Conclusions: The diffusion of the EFNS guidelines on neurophysiological tests and neuroimaging procedures was found to be very limited amongst neurologists and GPs. The physicians aware of the EFNS guidelines recommended neurophysiological tests to migraine patients less frequently and more appropriately than physicians who were not aware of them. The most frequent misconceptions regarding neurophysiological tests concerned their perceived capacity to discriminate between migraine and secondary headaches or between migraine and other primary headaches.
- 15 July 2009
- Published by Wiley in European Journal of Neurology
- Vol. 16 (8) , 937-942
Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non‐acute migraine patients: a questionnaire survey of neurologists and primary care physicians
Background and purpose: The main aims of this study were to evaluate: the diffusion, use and perception of the usefulness of the 2004 EFNS guidelines on neurophysiological testing in non‐acute headache patients; the frequency with which the different neurophysiological tests were recommended in non‐acute migraine patients by physicians aware or unaware of the guidelines; and the appropriateness of the reasons given for recommending neurophysiological tests. Methods: One hundred and fifty physicians selected amongst the members of the Italian societies of general practitioner (GPs), neurologists and headache specialists were contacted via e‐mail and invited to fill in a questionnaire specially created for the study. Results: Ninety‐two percent of the headache specialists, 8.6% of the neurologists and 0% of the GPs were already aware of the EFNS guidelines. A significantly higher proportion of headache specialists had not recommended any neurophysiological tests to the migraine patients they had seen in the previous 3 months, whereas these tests had frequently been prescribed by the GPs and neurologists. Overall, 80%, 42% and 42.6% of the reasons given by headache specialists, neurologists and GPs, respectively, for recommending neurophysiological testing in their migraine patients were appropriate (P < 0.01). Conclusions: The diffusion of the EFNS guidelines on neurophysiological tests and neuroimaging procedures was found to be very limited amongst neurologists and GPs. The physicians aware of the EFNS guidelines recommended neurophysiological tests to migraine patients less frequently and more appropriately than physicians who were not aware of them. The most frequent misconceptions regarding neurophysiological tests concerned their perceived capacity to discriminate between migraine and secondary headaches or between migraine and other primary headaches.
- 1 November 2008
- Published by SAGE Publications in Cephalalgia
- Vol. 28 (11) , 1196-1200
Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study
The aim of this study was to evaluate the rates and predictors of relapse, after successful drug withdrawal, in migraine patients with medication overuse headache (MOH) and low medical needs. The study population, study design, inclusion criteria and short-term effectiveness of the medication withdrawal strategies have been described elsewhere (Rossi et al., Cephalalgia 2006; 26:1097). Relapsers were defined as those patients fulfilling, at follow-up, the new International Classification of Headache Disorders, 2nd edn, appendix criteria for MOH. Complete datasets were available for 83 patients. At 1 year's follow up, the relapse rate was 20.5±. Univariate analysis showed that patients who relapsed had a longer duration of migraine with more than eight headache days/month, a longer duration of drug overuse, had tried a greater number of preventive treatments in the past, had a lower reduction of headache frequency after withdrawal, and had previously consulted a greater number of specialists. Binary logistic regression analysis was performed, and three variables emerged as significant predictors of relapse: duration of migraine with more than eight headache days/month [odds ratio (OR) 1.57, P = 0.01], a higher frequency of migraine after drug withdrawal (OR 1.48, P = 0.04) and a greater number of previous preventive treatments (OR 1.54, P = 0.01). In patients with migraine plus MOH and low medical needs, relapse seems to depend on a greater severity of baseline migraine.
- 1 November 2008
- Published by SAGE Publications in Cephalalgia
- Vol. 28 (11) , 1196-1200
Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study
The aim of this study was to evaluate the rates and predictors of relapse, after successful drug withdrawal, in migraine patients with medication overuse headache (MOH) and low medical needs. The study population, study design, inclusion criteria and short-term effectiveness of the medication withdrawal strategies have been described elsewhere (Rossi et al., Cephalalgia 2006; 26:1097). Relapsers were defined as those patients fulfilling, at follow-up, the new International Classification of Headache Disorders, 2nd edn, appendix criteria for MOH. Complete datasets were available for 83 patients. At 1 year's follow up, the relapse rate was 20.5±. Univariate analysis showed that patients who relapsed had a longer duration of migraine with more than eight headache days/month, a longer duration of drug overuse, had tried a greater number of preventive treatments in the past, had a lower reduction of headache frequency after withdrawal, and had previously consulted a greater number of specialists. Binary logistic regression analysis was performed, and three variables emerged as significant predictors of relapse: duration of migraine with more than eight headache days/month [odds ratio (OR) 1.57, P = 0.01], a higher frequency of migraine after drug withdrawal (OR 1.48, P = 0.04) and a greater number of previous preventive treatments (OR 1.54, P = 0.01). In patients with migraine plus MOH and low medical needs, relapse seems to depend on a greater severity of baseline migraine.
- 31 August 2008
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 16 (4) , 220-227
Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey
- 31 August 2008
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 16 (4) , 220-227
Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey
- 1 December 2006
- Published by SAGE Publications in Cephalalgia
- Vol. 26 (12) , 1427-1433
Headache Attributed to Infection: Observations on the IHS Classification (ICHD-II)
The aim of this study was to revise some topics in the chapter ‘Headache attributed to infections’ in the last International Headache Society (IHS) classification. The authors searched for original studies and reviews about headache associated with infections. A checklist was submitted to 15 neurologists to quantify the relevance, comprehensibility and coherence between definitions, criteria and comments for each paragraph. The following paragraphs were fully discussed: (1) headache attributed to lymphocytic meningitis. This topic, being rather heterogeneous, should be divided into different subgroups; (2) headache attributed to HIV/AIDS. Distinctive features are not specified and diagnostic criteria are rather confusing; and (3) chronic post-infection headache. Diagnostic criteria should be reconsidered as the symptom ‘pain’ is not the main diagnostic criterion. The authors propose the revision of three paragraphs of the new IHS classification to better define the most likely headache profile in specific CNS infections. The authors also underline the need to plan further ad hoc prospective studies.
- 1 December 2006
- Published by SAGE Publications in Cephalalgia
- Vol. 26 (12) , 1427-1433
Headache Attributed to Infection: Observations on the IHS Classification (ICHD-II)
The aim of this study was to revise some topics in the chapter ‘Headache attributed to infections’ in the last International Headache Society (IHS) classification. The authors searched for original studies and reviews about headache associated with infections. A checklist was submitted to 15 neurologists to quantify the relevance, comprehensibility and coherence between definitions, criteria and comments for each paragraph. The following paragraphs were fully discussed: (1) headache attributed to lymphocytic meningitis. This topic, being rather heterogeneous, should be divided into different subgroups; (2) headache attributed to HIV/AIDS. Distinctive features are not specified and diagnostic criteria are rather confusing; and (3) chronic post-infection headache. Diagnostic criteria should be reconsidered as the symptom ‘pain’ is not the main diagnostic criterion. The authors propose the revision of three paragraphs of the new IHS classification to better define the most likely headache profile in specific CNS infections. The authors also underline the need to plan further ad hoc prospective studies.
- 1 December 2006
- Published by SAGE Publications in Cephalalgia
- Vol. 26 (12) , 1485-1486
Bath-Related Headache: The First European Case
- 1 December 2006
- Published by SAGE Publications in Cephalalgia
- Vol. 26 (12) , 1485-1486
Bath-Related Headache: The First European Case